Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.

View in: PubMed

subject areas

Academic Medical Centers
Aged
Aged, 80 and over
Antineoplastic Agents
Benzodioxoles
Chicago
Humans
Male
Middle Aged
Neoplasm Metastasis
Prostatic Neoplasms, Castration-Resistant
Quinazolines

authors with profiles

Theodore Karrison
Peter H. O'Donnell
Russell Z. Szmulewitz
Walter M. Stadler